Cas:85344-77-0 TRH-Gly manufacturer & supplier

We serve Chemical Name:TRH-Gly CAS:85344-77-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

TRH-Gly

Chemical Name:TRH-Gly
CAS.NO:85344-77-0
Synonyms:PE-H-P-G;PYR-HIS-PRO-GLY-OH;THYROTROPIN-RELEASING HORMONE-GLY;pglu-his-pro-gly;PYR-HIS-PRO-GLY;GLP-HIS-PRO-GLY
Molecular Formula:C18H24N6O6
Molecular Weight:420.42000
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:1069.5ºC at 760 mmHg
Density:1.461g/cm3
Index of Refraction:1.611
PSA:173.59000
Exact Mass:420.17600
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like PE-H-P-G chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,GLP-HIS-PRO-GLY physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,GLP-HIS-PRO-GLY Use and application,GLP-HIS-PRO-GLY technical grade,usp/ep/jp grade.


Related News: Cost: Hedge prices of thick product lines + self-produced intermediates fluctuate, and sufficient supply of upstream raw materials can significantly promote the production of APIs. TRH-Gly manufacturer The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data. TRH-Gly supplier The FDA said its decision allows for the J&J doses to be used in the United States or exported. T TRH-Gly vendor In addition, due to environmental constraints, Yancheng Lianhua’s first pesticide project ANBE was put into operation at a slower pace than expected, and other pesticide projects were also put into operation. TRH-Gly factory The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.